Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LP7U
|
|||
| Drug Name |
AMV564
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1] | |
| Company |
Amphivena Therapeutics South San Francisco, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | Modulator | [1] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.